Back to News

Aug 30, 2016

Cure Forward Stresses Patient Data Access as Trial Matching Service Matures

Aug 30, 2016 |

Turna Ray

NEW YORK (GenomeWeb) – After opening up a beta version of its clinical trial matching platform to the public, Cure Forward is making headway in its goal to improve cancer patients' ability to access precision medicine by helping them obtain their genomic data from labs.

"We can do infinite things," Martin Naley, founder and chief strategy officer of Cure Forward, told GenomeWeb earlier this summer. "But it all begins with people getting their data and being able to apply it different ways."

Naley launched Cure Forward last year with $15 million in venture funding from Apple Tree Partners. During the 15 years he spent in leadership roles at companies like Invitrogen and Life Technologies, Naley often found himself fielding a lot of queries from friends and acquaintances about how to access precision medicine options.

He told GenomeWeb recently that felt he could always help his friends out by introducing them to someone else — a researcher, a genetic test provider, or a doctor — who could guide them to the next step. "That step always helped them to keep going in their care," Naley recalled, but he also realized that "there is a bigger need out there than just the people who know me."

In an effort to bring precision care to more patients, the Cambridge, Massachusetts-based firm offers services that are increasingly in demand as genomic profiling becomes a critical tool in the fight against cancer. Cure Forward helps cancer patients better understand the molecular features of their disease, connects them to clinical trials, and enables them to find others that have similar tumor profiles. Central to all these services are patients who have access to their medical and test reports, which Cure Forward also helps with.

On the education front, Cure Forward has created on its website "gene stories" for more than 40 genes implicated in cancer. Patients can explore the information to understand, for example, that when a piece of the ROS1 gene fuses with a piece from another gene, the fusions scramble the normal signals within cells and can lead to cancer.

One of the early lessons for Naley's team has been figuring out how to explain complex genomics concepts in oncology in a way that's accessible to patients. It's not just about "dumbing down" the concepts, Naley said, but about communicating from a place of empathy with people who have just found out they have cancer, may have never heard of DNA or precision medicine, and are "trying to figure out what the heck to do."

"I think we take it for granted as people who have lived in the world of precision medicine for a long time that the public is familiar with these principles of finding molecular targets in your body to fight your cancer," Naley said "But it turns out we're doing a lot of education work for the patients who are coming on to our [clinical trials exchange] platform."

Cure Forward's clinical trial exchange platform enables patients to post their anonymized profiles, including information about their cancer, treatments, molecular data, and location preferences, for 30 days. Clinical trial recruiters using the platform can see these patients during that time and invite them to participate in ongoing research.

Since last year, the company has been privately testing a beta version of the platform, but opened it up for the public to try out a few months ago. During that short time, the platform has gained several hundred registered users, patients are starting to post their information, and there have already been some matches, according to Naley.

The 30-day time frame during which patient profiles are available to recruiters is intended to account for the urgency in cancer care, as well as the challenges of study recruitment. Initially, Cure Forward had set a 10-day time frame, but Naley said that proved to be too quick a turnaround to facilitate matches.

A month allows more time for trial matching, he explained, but is short enough to allow recruiters to identify patients who are still interested in a specific study. It also encourages recruiters to regularly use the platform so they don't miss promising patient profiles that will not be available after a while. Beyond a month, it may be likely that a cancer patient has moved on in his or her care and is no longer interested in a particular trial.

An oft-cited statistic in cancer research is that between 3 percent and 6 percent of eligible patients actually partake in studies. The low participation numbers are particularly challenging for advancing precision medicine, which target molecular markers that are often rare in the population. A number of companies, such as Cure Forward, CollabRx (which last year merged with Medytox Solutions), and M2Gen are trying to address this difficulty by providing clinical trial matching services that factor in patients' molecular tumor profiles.

"It flips the trial finding [process] upside down," Naley said of Cure Forward's platform. "Instead of looking around for a trial, the trials show up in your mailbox." Trial recruiters don't have to wait for patients to apply to their trails. They can see available patients on the platform and invite them to join based on the information posted.

Cure Forward realizes revenue when patients accept clinical trial invitations from recruiters. Patients can post their information on the platform for free and the firm also doesn't charge recruiters or trial sponsors when they put up information about a study. But once a recruiter invites a patient who matches study criteria, and the patient accepts, that consumes tokens. Cure Forward provides recruiter clients an initial set of tokens with which to start using the platform, but once those runs out, they have to buy more.

In June, the company inked its first trial recruitment collaboration with a large pharmaceutical company, Novartis, which has said it will use the clinical trial exchange platform to identify participants for its studies. US Oncology Research, which offers more than 200 clinical trials around the country and provides care to more than 800,000 patients through its network, also said it would use Cure Forward's trial matching platform. According to Naley, Cure Forward has inked similar partnerships with other biotechs and a large contract research organization, but some of these deals aren't yet public.

The company is developing a community portal where patients can find others with similar molecular features driving their cancer, so they can "problem solve their disease together and learn from one another's experiences," Naley said.

Cure Forward hopes to launch a marketplace where patients can shop for second opinions, he added. Cancer patients will be able to share their clinical and genomic information with doctors and ask if they have ideas beyond the course initially recommended. The company will also create tools with which patients can easily donate their data to research.

All the services provide by Cure Forward, whether it's education, trial matching, or facilitating connections with doctors and patients, start with the patient having access to his or her medical data. This philosophy even dictates which labs Cure Forward partners with.

The company has inked partnerships with eight labs, which offer tumor profiling on next-generation sequencing panels, as well as exome and whole-genome sequencing. These labs have also committed to providing patients who request it access to their full data set generated through testing, which can contain information on benign genetic variants or variants of unknown significance that may not be included in a test report.

Naley said these labs share Cure Forward's guiding belief that "if you put data in people's hands, they may be able to do constructive things with it."

Cure Forward doesn't recommend specific tests to patients or that they get tested at a particular lab. Even if patients get tested from a non-partner provider, the company has created a data request letter they can use to ask for all the information that lab has in a structured format.

In this way, Cure Forward is also educating patients about their data access rights under the Health Insurance Portability and Accountability Act. Changes to the HIPAA Privacy Rule two years ago gave individuals the right to receive copies of their "designated record set" from HIPAA covered entities. A DRS, as defined in the HIPAA Privacy Rule, comprises medical, billing, payment, claims, health plan enrollment, case management, and any other records used to make decisions about an individual.

The US Department of Health and Human Services explained in a "Frequently Asked Questions" document this January that a DRS maintained by a genetic testing lab includes not only reports but also the "underlying information generated as part of the test." Moreover, labs that are HIPAA-covered entities and conduct NGS have to provide individuals who request information related to genomic testing "with a copy of the completed test report, the full gene variant information generated by the test, as well as any other information in the designated record set concerning the test."

Earlier this year, four patients who had previously received testing from Myriad Genetics exercised their rights under the HIPAA Privacy Rule and requested their DRS, specifically information on all genetic variants identified during testing. This exercise, which the patients carried out with the help of the American Civil Liberties Union, demonstrated that within the lab community and among patients there may be limited awareness of how broad patients' data access rights really are under HIPAA.

Initially, Myriad provided the patients with their test report, because, according to the company, this is usually what patients ask for. After conferring with the Office for Civil Rights and getting further clarification on what's included in a DRS, Myriad provided patients with the information they were requesting. A Myriad spokesperson noted though that no patient — before the four patients guided by the ACLU requested their DRS — had ever asked for anything beyond their test report.

In an effort to better comprehend data access rights under HIPAA, Cure Forward has consulted lawyers about the Privacy Rule and appreciates that "all data that's created [on a patient], whether it's reported out in a test report or not, is part of the designated record set," Naley said. "That's what a patient has a legal right to access."

Using Cure Forward's data request form patients are having success getting their data sets from labs, he added. "Even from places that are not our partner and have been reluctant to provide any data, using our data request letter we've been able to retrieve full data sets that go beyond what is in a patient's diagnostic test report," Naley said.

He claimed that the information from the DRS has even helped some patients get treatment options that they wouldn't have otherwise. The company, however, would not put GenomeWeb in touch with any of these patients. "HIPAA is about more than privacy. It's about data access," Naley said. "And we help people exercise that right to get that data from anywhere."

All news about Cure Forward

More News

Mar 09, 2017

Fight Colorectal Cancer Partners With Cure Forward

Read more

Feb 20, 2017

CleanSlate Centers' Officials Join District Attorney's Addiction Task Force

Read more

Feb 20, 2017

Indiana Medicaid Members Gain Access to Leading Addiction Treatment

Read more

Feb 13, 2017

Fast Company Honors Braeburn as a Top Ten Most Innovative Company in Biotech

Read more

Jan 13, 2017

Braeburn Pharmaceuticals’ Probuphine® Implant Receives J-Code

Read more

Jan 04, 2017

Opioid Addiction Treatment Leader CleanSlate Launches Center in Fort Wayne

Read more

Dec 19, 2016

CleanSlate Centers Adds Executive to East Division Leadership

Read more

Dec 12, 2016

National Opioid Addiction Treatment Leader CleanSlate Launches Center in Elkhart

Read more

Nov 21, 2016

Braeburn and CEO Behshad Sheldon Win Stevie Awards

Read more

Nov 17, 2016

Syntimmune Announces Appointment of David De Graaf, Ph.D., as CEO

Read more

Nov 14, 2016

Braeburn Pharmaceuticals and Camurus Announce Positive Top-line Phase 3 Results

Read more

Oct 31, 2016

Opioid Addiction Treatment Leader CleanSlate Launches Center in East Boston

Read more

Oct 27, 2016

​ Probuphine® Wins Popular Science’s “Best of What’s New” Award

Read more

Oct 24, 2016

Braeburn Pharmaceuticals and Camurus Expand Collaboration and License Agreement

Read more

Oct 21, 2016

Braeburn and Camurus announce the presentation of new data

Read more

Oct 04, 2016

OPTUM, CLEANSLATE TO EXPAND ACCESS TO OPIOID ADDICTION TREATMENT FOR MEMBERS

Read more

Oct 03, 2016

Opioid Addiction Treatment Leader CleanSlate Launches Center in Merrillville

Read more

Sep 30, 2016

Braeburn and Camurus Enroll First Patients in a Phase 3 Efficacy Trial

Read more

Sep 22, 2016

Cure Forward Names Consumer Healthcare and IT Veteran Frank Ingari as CEO

Read more

Sep 06, 2016

ROX Medical Raises $40M Financing

Read more

Aug 30, 2016

Cure Forward Stresses Patient Data Access as Trial Matching Service Matures

Read more

Aug 27, 2016

HeartWare Receives FDA Approval To Enroll Supplemental Patient Cohort In Trial

Read more

Aug 23, 2016

Medtronic Completes Acquisition of HeartWare International

Read more

Aug 15, 2016

National Opioid Addiction Treatment Leader CleanSlate Opens Center in Anderson

Read more

Aug 02, 2016

Cure Forward Selects Personal Genome Diagnostics

Read more

Jul 29, 2016

VytronUS, Inc. Raises $49 Million in Series C Financing

Read more

Jul 29, 2016

Apple Tree Bankrolls Johnson & Johnson Spinout Tusker Medical

Read more

Jul 20, 2016

Anthony Belott joins CleanSlate Centers as Chief Development Officer

Read more

Jul 19, 2016

Braeburn Pharmaceuticals Announces Probuphine Data Published

Read more

Jul 06, 2016

High-Tech Healthcare Helps Eliminate Unnecessary Hospital Visits

Read more

Jun 28, 2016

Cure Forward Announces First Trial Recruitment Collaboration

Read more

Jun 27, 2016

Medtronic to Expand Portfolio with Acquisition of HeartWare International

Read more

Jun 13, 2016

CleanSlate Centers names Gregory C. Marotta President & CEO

Read more

Jun 08, 2016

CleanSlate, a Massachusetts based addiction treatment center, expands nationally

Read more

May 26, 2016

FDA approves first buprenorphine implant for treatment of opioid dependence

Read more

Apr 20, 2016

Dermatology Services Company QualDerm Unveils $31.8M Growth Investment

Read more

Mar 22, 2016

Syntimmune Secures Second Tranche of $26 Million Series A Financing

Read more

Feb 22, 2016

Braeburn and Camurus Announce Initiation of a Phase 2 Study

Read more

Feb 17, 2016

Corvidia Therapeutics Raises $26M in a Series A Financing

Read more

Feb 01, 2016

Braeburn Pharmaceuticals and Knight Therapeutics Announce

Read more

Jan 14, 2016

Titan Pharmaceuticals and Braeburn Pharmaceuticals Announce FDA Advisory

Read more

Dec 15, 2015

Braeburn Pharmaceuticals and Camurus Announces Start of Phase 3 Trial

Read more

Dec 09, 2015

Titan Pharmaceuticals and Braeburn Pharmaceuticals Announce Date of FDA Review

Read more

Nov 10, 2015

Tokai Pharmaceuticals Reports Third Quarter 2015 Financial Results

Read more

Nov 09, 2015

CleanSlate Launches STAT Campaign for Physician Awareness of PA Opioid Epidemic

Read more

Nov 04, 2015

FDA Grants Fast Track Designation for Development of CAM2038

Read more

Oct 01, 2015

Pharmatech and Cure Forward to Accelerate Oncology Clinical Trial Enrollment

Read more

Sep 28, 2015

FDA Accepts Braeburn’s Resubmission of Probuphine NDA for Review

Read more

Sep 22, 2015

Cure Forward Launches Precision Medicine Engagement Platform for Cancer Patients

Read more

Sep 20, 2015

Paul L. Chabot Joins CleanSlate Centers as the New CIO

Read more

Sep 17, 2015

Braeburn Pharmaceuticals Commends HHS Secretary Burwell

Read more

Sep 14, 2015

Patrick J. Murphy Joins CleanSlate Centers as the New Chief Financial Officer

Read more

Sep 04, 2015

Geisinger Health Plan Establishes Relationship with CleanSlate Centers

Read more

Aug 12, 2015

Tokai Pharmaceuticals Reports Second Quarter 2015 Results

Read more

Jul 30, 2015

Abbott to Broaden Foundation in Structural Heart Therapies

Read more

Jun 24, 2015

Tokai Announces Initiation of Phase 3 ARMOR3-SV Trial of Galeterone

Read more

Jun 23, 2015

Gregory C. Marotta Joins CleanSlate Centers as the New Chief Operating Officer

Read more

Jun 18, 2015

Cure Forward Receives $15 Million in Series A Financing

Read more

Jun 08, 2015

Braeburn Reports Positive Results From Phase 3 Study

Read more

Jun 01, 2015

Patrick J Kennedy Accepts Seat on Board of Directors at CleanSlate Centers

Read more

May 12, 2015

Tokai Pharmaceuticals Reports First Quarter 2015 Financial Results

Read more

Apr 14, 2015

Tendyne Announces First Patient Enrolled in US Trial

Read more

Apr 09, 2015

Tendyne Raises $25 Million in Series C

Read more

Apr 06, 2015

VytronUS, Inc. Attracts Industry Veteran John Pavlidis as New President and CEO

Read more

Mar 12, 2015

Tokai Reports Fourth Quarter and Full Year 2014 Financial Results

Read more

Feb 12, 2015

Aileron Therapeutics Initiates Phase 1 Cancer Study of ALRN-6924

Read more

Dec 15, 2014

The Tendyne TMVI system was successfully implanted in the first patient

Read more

Dec 02, 2014

Tendyne Announces Successful First Human Implants of TMVI

Read more

Nov 19, 2014

Tokai Pharmaceuticals Presents Updated Interim Galeterone ARMOR2 Data

Read more

Nov 10, 2014

Tokai Pharmaceuticals Reports Third Quarter 2014 Financial Results

Read more

Oct 29, 2014

​VytronUS, Inc. Raises $31.6 Million in Series B

Read more

Oct 29, 2014

Aileron Therapeutics Secures $33 Million in Series E

Read more

Sep 24, 2014

Braeburn Pharmaceuticals’ Probuphine® Study Hits Enrollment Milestone

Read more

Sep 23, 2014

Tokai Pharmaceuticals Announces Closing of Initial Public Offering

Read more

Jun 02, 2014

Tokai Pharmaceuticals Presents New Clinical Data for Galeterone

Read more

May 16, 2014

Updated Phase 2 Clinical Data on Tokai Pharmaceuticals’ Galeterone

Read more

Mar 07, 2014

Titan Announces Agreement in Principle for Probuphine Clinical Study

Read more

Feb 03, 2014

Tokai's Reformulated Galeterone Demonstrates Robust PSA Reductions

Read more

Jan 13, 2014

New Phase 2 Clinical Data on Tokai Pharmaceuticals’ Galeterone

Read more

Nov 18, 2013

Aileron Therapeutics has secured $30 million in Series E equity financing

Read more

Nov 15, 2013

Titan Pharmaceuticals Announces $5 Million Equity Investment

Read more

Sep 26, 2013

Frank E. Young, Former FDA Commissioner, Joins Braeburn Pharmaceuticals as EVP

Read more

Aug 15, 2013

Aileron Therapeutics Publishes Data

Read more

Aug 13, 2013

Titan Announces Publication of Phase 3 Probuphine Data in Additiction

Read more

Aug 09, 2013

HeartWare Presentation At The Canaccord Genuity 2013 Annual Growth Conference

Read more

Aug 08, 2013

HeartWare International Reports $50.8 Million In Second Quarter 2013 Revenue

Read more

Jun 17, 2013

HeartWare Receives Conditional Approval From FDA

Read more

May 15, 2013

Tokai Pharmaceuticals Announces $35.5 Million Series E Financing

Read more

May 07, 2013

Aileron Successfully Completes First-Ever Stapled Peptide Clinical Trial

Read more

Apr 29, 2013

HeartWare International Reports $49.2 Million In First Quarter 2013 Revenue

Read more

Apr 10, 2013

Aileron Therapeutics Presents New Preclinical Data on Stapled Peptide

Read more

Apr 04, 2013

Tokai Announces Presentation of Galeterone Mechanism of Action Data

Read more

Mar 28, 2013

Tokai Pharmaceuticals Announces Appointment of Jodie Morrison as CEO

Read more

Mar 22, 2013

Titan Announces FDA Advisory Committee Recommends Approval of Probuphine®

Read more

Mar 14, 2013

Titan announces date of FDA Advisory Committee Review of PROBUPHINE®

Read more

Mar 12, 2013

HeartWare Announces Pricing of Public Offering of Common Stock

Read more

Mar 04, 2013

Tokai to Present Data on Galeterone in Advanced Prostate Cancer

Read more

Jan 14, 2013

Aileron Secures $12 Million for First-Ever Stapled Peptide Clinical Trial

Read more

Jan 07, 2013

HeartWare International Announces Preliminary Fourth Quarter 2012 Revenues

Read more

Jan 02, 2013

Probuphine® Receives FDA Priority Review Designation

Read more

Dec 17, 2012

Titan Licenses Exclusive Probuphine® Commercialization Rights in U.S. & Canada

Read more

Dec 13, 2012

Tokai Pharmaceuticals Doses First Patient in a Phase 2 Study of Galeterone

Read more

Nov 20, 2012

HeartWare Receives FDA Approval for HeartWare Ventricular Assist System

Read more

Nov 09, 2012

HeartWare Reports Third Quarter 2012 Results

Read more

Aug 07, 2012

HeartWare Reports Second Quarter 2012 Results

Read more

Aug 02, 2012

HeartWare Completes Acquisition Of World Heart Corporation

Read more

Jun 12, 2012

Tokai Pharmaceuticals’ Galeterone Receives Fast Track Designation From the FDA

Read more

Apr 25, 2012

FDA Advisory Committee Votes in Favor of HeartWare® Ventricular Assist System

Read more

Apr 02, 2012

Positive Phase 1 data presented

Read more

Mar 29, 2012

HeartWare International Expands Intellectual Property and Technology Portfolio

Read more

Mar 14, 2012

10 Top Next-Gen Biotech Platforms

Read more

Feb 16, 2012

HeartWare International Reports Fourth Quarter 2011 Revenues of $23.1 Million

Read more

Nov 17, 2011

Aileron expands stapled peptide drug collaboration with Roche

Read more

Sep 20, 2011

Tokai Pharmaceuticals Raises $23 Million in Funding

Read more

Sep 20, 2011

Tokai Snaps Up $23M From Novartis and Apple Tree

Read more

Sep 20, 2011

Tokai lands new CEO, $23M venture round for PhIIb cancer study

Read more

Jun 16, 2011

FDA Grants Accelerated Approval of ISTODAX(R)

Read more

May 05, 2011

HeartWare International Reports First Quarter 2011 Revenues of $18.0 Million

Read more

Apr 15, 2011

HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial

Read more

Mar 24, 2011

HeartWare International Receives Approval From the TGA in Australia

Read more

Feb 28, 2011

FDA Grants Priority Review For ISTODAX(R) sNDA

Read more

Feb 24, 2011

HeartWare International Reports Fourth Quarter 2010 Revenues of $20.9 Million

Read more

Jan 24, 2011

HeartWare Receives Third Patient Allotment From FDA

Read more

Dec 28, 2010

HeartWare Files PMA Application for FDA Approval

Read more

Dec 15, 2010

HeartWare Announces Completion of Concurrent Public Offerings

Read more

Dec 10, 2010

HeartWare Announces Pricing of Concurrent Public Offerings

Read more

Dec 09, 2010

HeartWare International, Inc. Announces Concurrent Public Offerings

Read more

Dec 05, 2010

New Clinical Data Evaluating ISTODAX(R) in Pivotal Open-Label Phase II Study

Read more

Nov 14, 2010

HeartWare 5-Ounce Pump Extends Lives in Heart Failure Patients

Read more

Nov 14, 2010

HeartWare Achieves Primary Endpoint

Read more

Aug 24, 2010

Roche Backs New Method for Drug Delivery to Cells

Read more

Aug 24, 2010

Roche Enters $1.1B Deal With Aileron To Produce New Drugs

Read more

Aug 01, 2010

Stapled Peptides on the cover of the August issue of Nature Chemical Biology

Read more

Jun 24, 2010

HeartWare Announces Board Succession

Read more

Jun 14, 2010

HeartWare Receives Conditional FDA Approval

Read more

Apr 23, 2010

HeartWare Data From First 100 Patients

Read more

Apr 07, 2010

HeartWare Receives FDA Approval of Continued Access Protocol

Read more

Feb 22, 2010

HeartWare Announces Early Conclusion of Enrollment

Read more

Feb 02, 2010

HeartWare Announces Completion of Public Offering of Common Stock

Read more

Jan 26, 2010

HeartWare Announces Commencement of Public Offering of Common Stock

Read more

Dec 07, 2009

Celgene to Acquire Gloucester Pharmaceuticals

Read more

Nov 27, 2009

Tokai eyes novel weapon to battle prostate cancer

Read more

Nov 11, 2009

Aileron Therapeutics Collaborators Publish In Vivo Research in Nature

Read more

Nov 05, 2009

FDA Approves Gloucester's ISTODAX® for Cutaneous T-cell Lymphoma

Read more

Oct 10, 2009

Tokai Pharmaceuticals Initiates ARMOR Program for TOK-001

Read more

Sep 02, 2009

FDA Advisory Committee Recommends Gloucester's Romidepsin for Approval

Read more

Aug 25, 2009

Gloucester raises $29 million

Read more

Aug 21, 2009

HeartWare International Surpasses 50 Implants In The US

Read more

Aug 17, 2009

HeartWare International, Inc. Closes US$60 Million Financing

Read more

Jun 08, 2009

Aileron Therapeutics Closes $40M Financing To Advance Stapled Peptide Platform

Read more

Jun 01, 2009

“Emerging Drug Developer” Tokai Pharmaceuticals

Read more

Oct 22, 2008

Aileron Advances First Stapled Peptide Drug Candidate

Read more